While LY2157299 has been evaluated in a phase II clinical trial in metastatic breast cancer patients (NCT02538471), the benefits of suppressing CSC by inhibiting TGFβ remain to be determined in a clinical setting. The gene discussed is TGFB1; the disease is breast carcinoma.